Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 4Breast Neoplasms 4Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neutropenia 1Multiple Myeloma 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Breastcancer 1Bone Neoplasms 1

Interventions

niraparib 4olaparib 2apatinib 2Sevoflurane 2Saline Solution 2Propofol 2Carboplatin 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1palbociclib 1liposomal doxorubicin 1lenvatinib 1gadofosveset trisodium 1fosaprepitant 1ferrous fumarate 1Tranexamic Acid 1Trabectedin 1Sunitinib 1Sodium Chloride 1Pharmacokinetics 1Patient-Specific Modeling 1Pafolacianine 1Paclitaxel 1LY 353381 1Injections 1Indocyanine Green 1Folic Acid 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Ovarian Neoplasms × pegylated granulocyte colony-stimulating factor × Clear all
NCT03858166 2024-01-05

Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

Shandong University

Phase 4 Terminated
68 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡